Enzymatic absorption promoters could enable oral delivery of peptide drugs like semaglutide and insulin

Enzymatic absorption promoters (protease inhibitors, mucus-degrading enzymes, tight junction openers) could overcome GI barriers to enable oral delivery of peptide drugs, with emerging strategies showing promise for non-invasive administration.

RPEP-136782025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Three categories of enzymatic promoters: protease inhibitors (prevent degradation), mucolytic enzymes (clear mucus barrier), tight junction openers (enable paracellular transport). Applicable to oral, nasal, pulmonary peptide delivery.

Key Numbers

How They Did This

Narrative review of enzymatic strategies for improving non-invasive peptide drug absorption.

Why This Research Matters

Most peptide drugs (insulin, GLP-1 agonists, growth hormones) require injection—limiting patient compliance and access. Enabling oral delivery would transform treatment for millions of patients with diabetes, obesity, and hormonal conditions.

The Bigger Picture

The holy grail of peptide drug delivery—effective oral administration—is getting closer through enzymatic absorption technology. Combined with peptide engineering and nanoformulation, these approaches could make injectable peptides obsolete.

What This Study Doesn't Tell Us

Review of emerging technology. Most strategies are preclinical. Safety of chronic mucosal permeability enhancement needs evaluation. Bioavailability often remains low.

Questions This Raises

  • ?Which combination of absorption promoters achieves sufficient oral bioavailability?
  • ?Are chronic mucosal permeability changes safe long-term?
  • ?Could enzymatic promoters enable oral insulin with practical bioavailability?

Trust & Context

Key Stat:
From injection to pill Enzymatic absorption promoters could overcome the three main barriers to oral peptide delivery: enzyme degradation, mucus, and tight epithelial junctions
Evidence Grade:
Technology review of preclinical and emerging approaches. Promising but most strategies not yet clinically validated.
Study Age:
Published in 2025.
Original Title:
Enzymatic absorption promoters for non-invasive peptide delivery.
Published In:
Journal of controlled release : official journal of the Controlled Release Society, 382, 113675 (2025)
Database ID:
RPEP-13678

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Why can't most peptide drugs be taken as pills?

Peptide drugs like insulin are proteins that get destroyed by stomach acid and digestive enzymes, blocked by intestinal mucus, and cannot cross the tight barriers between gut cells. Enzymatic absorption promoters address each of these problems to enable oral delivery.

Will we ever have truly effective oral insulin?

It is getting closer. This review catalogs new enzymatic strategies that protect peptides from digestion, clear mucus barriers, and open temporary pathways through gut walls. Combined with advances in peptide engineering, oral insulin with practical bioavailability may be achievable within the next decade.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-13678·https://rethinkpeptides.com/research/RPEP-13678

APA

Steiger, Marilena Bohley; Steinauer, Angela; Gao, Daniel; Cerrejon, David Klein; Krupke, Hanna; Heussi, Miguel; Merkl, Padryk; Klipp, Alexander; Burger, Michael; Martin-Olmos, Cristina; Leroux, Jean-Christophe. (2025). Enzymatic absorption promoters for non-invasive peptide delivery.. Journal of controlled release : official journal of the Controlled Release Society, 382, 113675. https://doi.org/10.1016/j.jconrel.2025.113675

MLA

Steiger, Marilena Bohley, et al. "Enzymatic absorption promoters for non-invasive peptide delivery.." Journal of controlled release : official journal of the Controlled Release Society, 2025. https://doi.org/10.1016/j.jconrel.2025.113675

RethinkPeptides

RethinkPeptides Research Database. "Enzymatic absorption promoters for non-invasive peptide deli..." RPEP-13678. Retrieved from https://rethinkpeptides.com/research/steiger-2025-enzymatic-absorption-promoters-for

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.